Li B - Search Results

1

Distribution of ALK Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with Crizotinib.

Su Y, Long X, Song Y, Chen P, Li S, Yang H, Wu P, Wang Y, Bing Z, Cao Z, Cao L, Wu Y, Zhang Z, Liu J, Li B, Xiang J, Ma K, Zhang T, Zhang L, Mao X, Liu H, Xing P, Liang N. Su Y, et al. Among authors: li s, li b. Target Oncol. 2019 Apr;14(2):159-168. doi: 10.1007/s11523-019-00631-x. Target Oncol. 2019. PMID: 30895431

2

Frequency, clinical features and differential response to therapy of concurrent ALK/EGFR alterations in Chinese lung cancer patients.

Liu J, Mu Z, Liu L, Li K, Jiang R, Chen P, Zhou Q, Jin M, Ma Y, Xie Y, Xiang J, Li B, Ma Y, Mao X, Zhang L, Zhang T, Wu D. Liu J, et al. Among authors: li k, li b. Drug Des Devel Ther. 2019 May 23;13:1809-1817. doi: 10.2147/DDDT.S196189. eCollection 2019. Drug Des Devel Ther. 2019. PMID: 31213769 Free PMC article.

3

Clinical Characteristics and Molecular Patterns of RET-Rearranged Lung Cancer in Chinese Patients.

Zhang K, Chen H, Wang Y, Yang L, Zhou C, Yin W, Wang G, Mao X, Xiang J, Li B, Zhang T, Fei S. Zhang K, et al. Among authors: li b. Oncol Res. 2019 May 7;27(5):575-582. doi: 10.3727/096504018X15344979253618. Epub 2018 Aug 21. Oncol Res. 2019. PMID: 30131091 Free PMC article.

4

Characterization of MET exon 14 alteration and association with clinical outcomes of crizotinib in Chinese lung cancers.

Yang H, Zhou Z, Lin L, Yang M, Li C, Li Z, Yu X, Lizaso A, Han-Zhang H, Li B, Xiang J, Mao X, Xu Q, Zhang Y, Yang N. Yang H, et al. Among authors: li c, li z, li b. Lung Cancer. 2020 Oct;148:113-121. doi: 10.1016/j.lungcan.2020.08.009. Epub 2020 Aug 19. Lung Cancer. 2020. PMID: 32889305

5

The utilization of next-generation sequencing to detect somatic mutations and predict clinical prognosis of Chinese non-small cell lung cancer patients.

Cao L, Long L, Li M, Yang H, Deng P, Mao X, Xiang J, Li B, Zhang T, Hu C. Cao L, et al. Among authors: li m, li b. Onco Targets Ther. 2018 May 8;11:2637-2646. doi: 10.2147/OTT.S155995. eCollection 2018. Onco Targets Ther. 2018. PMID: 29780256 Free PMC article.

6

Clinical characterization of ERBB2 exon 20 insertions and heterogeneity of outcomes responding to afatinib in Chinese lung cancer patients.

Liu Z, Wu L, Cao J, Yang Z, Zhou C, Cao L, Wu H, Shen H, Jin M, Zhang Y, Mao X, Xiang J, Ma K, Li B, Zhang T, Hu Y. Liu Z, et al. Among authors: li b. Onco Targets Ther. 2018 Oct 23;11:7323-7331. doi: 10.2147/OTT.S173391. eCollection 2018. Onco Targets Ther. 2018. PMID: 30425522 Free PMC article.

7

Characterization of acquired receptor tyrosine-kinase fusions as mechanisms of resistance to EGFR tyrosine-kinase inhibitors.

Xu H, Shen J, Xiang J, Li H, Li B, Zhang T, Zhang L, Mao X, Jian H, Shu Y. Xu H, et al. Among authors: li h, li b. Cancer Manag Res. 2019 Jul 9;11:6343-6351. doi: 10.2147/CMAR.S197337. eCollection 2019. Cancer Manag Res. 2019. PMID: 31372039 Free PMC article.

8

Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib.

Kang J, Chen HJ, Wang Z, Liu J, Li B, Zhang T, Yang Z, Wu YL, Yang JJ. Kang J, et al. Among authors: li b. J Thorac Oncol. 2018 Apr;13(4):e49-e53. doi: 10.1016/j.jtho.2017.10.028. Epub 2017 Nov 8. J Thorac Oncol. 2018. PMID: 29128427 Free article. No abstract available.

9

Comparative study on the mutational profile of adenocarcinoma and squamous cell carcinoma predominant histologic subtypes in Chinese non-small cell lung cancer patients.

Ding Y, Zhang L, Guo L, Wu C, Zhou J, Zhou Y, Ma J, Li X, Ji P, Wang M, Zhu W, Shi C, Li S, Wu W, Zhu W, Xiao D, Fu C, He Q, Sun R, Mao X, Lizaso A, Li B, Han-Zhang H, Zhang Z. Ding Y, et al. Among authors: li s, li x, li b. Thorac Cancer. 2020 Jan;11(1):103-112. doi: 10.1111/1759-7714.13208. Epub 2019 Nov 6. Thorac Cancer. 2020. PMID: 31692283 Free PMC article.

10

HER2 transmembrane domain mutation: comprehensive characteristics and real-world evidence of treatment response in Chinese lung adenocarcinoma.

Jia Z, Xing J, Li J, Wang W, Wang Y, Song Y, Yang X, Xue J, Ye J, Li B, Han-Zhang H, Zhao J, Zhang X, Peng F, Chen F, Chen X, Lu Y, Ying S, Wu D, Zhang X, Ma C, Lai L, Ma S, Liang D, Liu P, Li X, Liang N, Li S. Jia Z, et al. Among authors: li s, li j, li x, li b. Transl Lung Cancer Res. 2021 Mar;10(3):1383-1396. doi: 10.21037/tlcr-21-107. Transl Lung Cancer Res. 2021. PMID: 33889517 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

46,364 results

Search Page

Filters